02315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 60.60
−5.53%Year over year
Reported trailing growth
- Revenue
- +100.9%
- EBITDA
- +401.6%
- EBIT
- +216.4%
- EPS
- +161.2%
- Free cash flow
- +196.8%
- Operating cash flow
- +432.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +37.2%
- EBITDA
- +38.1%
- EBIT
- +69.5%
- Net income
- +416.4%
- EPS
- +410.1%
- Free cash flow
- +62.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026